Four things to know:
1. CytoDyn is enrolling patients in two COVID-19 clinical trials: one for people with mild-to-moderate symptoms and another for those in critical condition.
2. The company began treatment on 12 COVID-19 patients in its Phase 2 mild-to-moderate trial and a site has been approved for 390 patients in its Phase 2b/3 severe trial, beginning April 14.
3. So far, CytoDyn has treated more than 30 patients at four hospitals and clinics in the U.S.
4. On April 13, the company appointed Scott Kelly, MD, as CMO and head of business development. Dr. Kelly has served as director of the spine center at Atlanta-based Resurgens Orthopaedics since 2007.
More articles on devices:
COVID-19 eases telemedicine’s shackles, expansion looks bright for orthopedics
Life Spine, Northern Light Health & more: 5 spine, orthopedic partnerships in the past month
Spinal robotics market to hit $320M by 2026: 3 updates
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.